CDKN1B and prostate carcinoma: CDKN1B alterations have been reported in breast cancers and prostate carcinomas [45,46,47] as well as in small intestine neuroendocrine tumors (SI-NETs), where mutations of CDKN1B represent one of the most frequent gene alterations [48,49].